DOXOrubicin Hydrochloride Liposome Injection
Sun Pharma recalls DOXOrubicin Liposome Injection 50 mg/25 mL vials due to glass particulate matter.
Consumers who have this product should stop using it immediately and contact their healthcare provider for guidance. For further instructions, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555.
Recall at a glance
- Quantity recalled
- 675 vials
Why it was recalled
Sun Pharmaceutical Industries is recalling DOXOrubicin Hydrochloride Liposome Injection, 50 mg/25 mL (2 mg/mL), 25 mL single-dose vials, due to the presence of glass particulate matter. Administration of a product with particulate matter may cause serious adverse events, including blockage of blood vessels, which can be life-threatening.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Aisling DOXOrubicin Hydrochloride Liposome Injection, 50mg 25 mL
- Best-by
- 05/2027
- NDC
- 72603-200-01
- Batch
- HAG2581B
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other recent recalls from SUN PHARMACEUTICAL INDUSTRIES INC
Editorial summary by Recall Canary · summary updated 2026-08-04 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification